Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients

Solaro, Claudio; Bergamaschi, Roberto; Rezzani, C.; Mueller, Margit; Trabucco, Erika; Bargiggia, Valeria; Dematteis, Francesca; Mattioda, Alessandra; Cimino, Vincenzo; Restivo, Domenico A.; Patti, Francesco; Cavalla, Paola

doi:10.1097/wnf.0b013e3182996400

Cited by 33 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, animal models have provided increasing evidence of the possible neuroprotective and neurodegenerative actions of fluoxetine [28]. Duloxetine was the second most prescribed antidepressants observed in our study, which is not unexpected because an open-label study demonstrated its safety, tolerance, and efficacy in reducing depression among individuals with MS [29]. Existing studies have also demonstrated the benefits of using other commonly prescribed antidepressants such as escitalopram [30], sertraline [31], and paroxetine [32] which were observed in our study to a lesser degree.…”

Section: Discussionmentioning

confidence: 68%

Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States

Bhattacharjee

Goldstone

et al. 2017

Multiple Sclerosis International

View full text Add to dashboard Cite

Background. There is little information regarding depression treatment patterns among adults with MS and depression in ambulatory settings at national level in the United States (US). Objectives. The objectives of this study were to identify patterns and predictors of depression treatment in ambulatory settings in US among adults with MS and depression. Methods. A cross-sectional study was conducted by pooling multiple years (2005–2011) of National Ambulatory Medical Care Survey and the outpatient department of the National Hospital Ambulatory Medical Care Survey data. The final study sample was comprised of ambulatory visits among adults with MS and depression. Dependent variable of this study was pharmacological treatment for depression with or without psychotherapy. Predictors of depression treatment were determined by conducting multivariable logistic regression. Results. Out of all ambulatory visits involving MS diagnosis, 20.59% also involved a depression diagnosis. Depression treatment was observed in 57.25% of the study population. Fluoxetine was the most prescribed individual antidepressant. Age and total number of chronic diseases were significant predictors of depression treatment. Conclusion. Approximately six out of ten ambulatory visits involving MS and depression recorded some form of depression treatment. Future longitudinal studies should examine health outcomes associated with depression treatment in this population.

show abstract

Section: Discussionmentioning

confidence: 68%

Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States

Bhattacharjee

Goldstone

et al. 2017

Multiple Sclerosis International

View full text Add to dashboard Cite

show abstract

“…Treatment of MS patients with duloxetine, a SNRI (Solaro et al . ), reduced depression and fatigure; however, neurological symptoms were not evaluated. It has also been reported that treatment with phosphodiesterase inhibitors, which prevent breakdown of cAMP, provides benefit (Suzumura et al .…”

Section: Reducing Na Loss and Lc Damage In Human Diseasesmentioning

confidence: 99%

“…Treatment with a mixture of lofepramine (a NARI that is metabolized to desipramine) and phenyalanine (a precursor of tyrosine) relieved symptoms of MS (Loder et al 2002;Wade et al 2002) as well as reduced lesion volume (Puri et al 2001) in a relatively large cohort (n = 69 drug-treated and n = 69 placebo-treated) of patients. Treatment of MS patients with duloxetine, a SNRI (Solaro et al 2013), reduced depression and fatigure; however, neurological symptoms were not evaluated. It has also been reported that treatment with phosphodiesterase inhibitors, which prevent breakdown of cAMP, provides benefit (Suzumura et al 2000), although it is likely that cAMP levels are due not only to NA activation of bARs but to other activators of adenylate cyclase activity.…”

Section: Vindeburnolmentioning

confidence: 99%

Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system

Feinstein

Kalinin

Braun

2016

Journal of Neurochemistry

140

128

View full text Add to dashboard Cite

Aside from its roles in as a classical neurotransmitter involved in regulation of behavior, noradrenaline (NA) has other functions in the CNS. This includes restricting the development of neuroinflammatory activation, providing neurotrophic support to neurons, and providing neuroprotection against oxidative stress. In recent years, it has become evident that disruption of physiological NA levels or signaling is a contributing factor to a variety of neurological diseases and conditions including Alzheimer's disease (AD) and Multiple Sclerosis. The basis for dysregulation in these diseases is, in many cases, due to damage occurring to noradrenergic neurons present in the locus coeruleus (LC), the major source of NA in the CNS. LC damage is present in AD, multiple sclerosis, and a large number of other diseases and conditions. Studies using animal models have shown that experimentally induced lesion of LC neurons exacerbates neuropathology while treatments to compensate for NA depletion, or to reduce LC neuronal damage, provide benefit. In this review, we will summarize the anti-inflammatory and neuroprotective actions of NA, summarize examples of how LC damage worsens disease, and discuss several approaches taken to treat or prevent reductions in NA levels and LC neuronal damage. Further understanding of these events will be of value for the development of treatments for AD, multiple sclerosis, and other diseases and conditions having a neuroinflammatory component.

show abstract

“…Some reports studied the use of antidepressant drugs in MS 7–10 , all of which indicated their beneficial effects regarding depression related symptoms. Indeed, very few studies investigated the potential immunosuppressive effect of fluoxetine 11 and sertraline 12 in animal models of MS. On the other hand, only one study in MS patients with major depression showed the efficacy of fluvoxamine 8 .…”

Section: Introductionmentioning

confidence: 99%

Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis

Ghareghani

Zibara

Sadeghi

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Multiple Sclerosis (MS) require medications controlling severity of the pathology and depression, affecting more than half of the patients. In this study, the effect of antidepressant drug fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in vitro and in vivo. Nanomolar concentrations of fluvoxamine significantly increased cell viability and proliferation of neural stem cells (NSCs) through increasing mRNA expression of Notch1, Hes1 and Ki-67, and protein levels of NICD. Also, physiological concentrations of fluvoxamine were optimal for NSC differentiation toward oligodendrocytes, astrocytes and neurons. In addition, fluvoxamine attenuated experimental autoimmune encephalomyelitis (EAE) severity, a rat MS model, by significantly decreasing its clinical scores. Moreover, fluvoxamine treated EAE rats showed a decrease in IFN-γ serum levels and an increase in IL-4, pro- and anti-inflammatory cytokines respectively, compared to untreated EAE rats. Furthermore, immune cell infiltration and demyelination plaque significantly decreased in spinal cords of fluvoxamine-treated rats, which was accompanied by an increase in protein expression of MBP and GFAP positive cells and a decrease in lactate serum levels, a new biomarker of MS progression. In summary, besides its antidepressant activity, fluvoxamine stimulates proliferation and differentiation of NSCs particularly toward oligodendrocytes, a producer of CNS myelin.

show abstract

Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients

Abstract: The results suggest that duloxetine is well tolerated, safe, and effective in reducing depression and fatigue in MS patients.

Cited by 33 publications

References 23 publications

Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States

Depression Treatment among Adults with Multiple Sclerosis and Depression in Ambulatory Care Settings in the United States

Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system

Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis

Contact Info

Product

Resources

About